(VIANEWS) - Provident Bancorp (PVBC), Physicians Realty Trust (DOC), Exponent (EXPO) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Provident Bancorp (PVBC)
25.5% sales growth and 6.87% return on equity
Provident Bancorp, Inc. is the bank holding company of The Provident Bank. It provides financial services for individuals, small and medium-sized businesses throughout the United States.
Provident Bancorp's sales growth this year is expected to be 28.1% and 18.3% for next year.
Year-on-year quarterly revenue growth grew by 6.4%, now sitting on 62.71M for the twelve trailing months.
Volume
Today's last reported volume for Provident Bancorp is 12238 which is 55.91% below its average volume of 27763.
Provident Bancorp's sales growth for the next quarter is 25.5%. The company's growth estimates for the present quarter and the next is 8.3% and 61.1%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.87%.
Volatility
Provident Bancorp's last day, last week, and last month's current intraday variation average was 0.57%, 0.93%, and 0.99%, respectively.
Provident Bancorp's highest amplitude of average volatility was 3.03% (day), 2.24% (last week), and 2.16% (last month), respectively.
Provident Bancorp's Stock Yearly Top and Bottom Value
Provident Bancorp's stock is valued at $15.60 at 11:22 EST, way below its 52-week high of $20.14 and above its 52-week low of $14.77.
Provident Bancorp's Moving Average
Provident Bancorp's value is under its 50-day moving average of $15.91 and below its 200-day moving average of $16.94.2. Physicians Realty Trust (DOC)
14.7% sales growth and 3.02% return on equity
Physicians Realty Trust, a privately managed healthcare real estate firm, is organized to purchase, develop, manage, and own healthcare properties that can be leased to doctors, hospitals, and other healthcare providers.
Physicians Realty Trust's sales growth this year is anticipated to be 13.5% and 5.5% for next year.
Year-on-year quarterly revenue growth grew by 4.3%, now sitting on 456.13M for the twelve trailing months.
Volume
Today's last reported volume for Physicians Realty Trust is 4251730 which is 86.63% above its average volume of 2278060.
Physicians Realty Trust's sales growth for the next quarter is 14.7%. The company's growth estimates for the present quarter and the next is a negative 12.5% and negative -12.5%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.02%.
Volatility
Physicians Realty Trust's last day, last week, and last month's current intraday variation average was 3.09%, 1.87%, and 1.24%, respectively.
Physicians Realty Trust's highest amplitude of average volatility was 2.75% (day), 2.47% (last week), and 2.00% (last month), respectively.
Physicians Realty Trust's Stock Yearly Top and Bottom Value
Physicians Realty Trust's stock is valued at $17.14 at 11:22 EST, way below its 52-week high of $19.59 and above its 52-week low of $16.07.
Physicians Realty Trust's Moving Average
Physicians Realty Trust's value is below its 50-day moving average of $17.24 and below its 200-day moving average of $18.09.3. Exponent (EXPO)
13.4% sales growth and 26% return on equity
Exponent, Inc., along with its affiliates, is a global science and engineering consulting firm.
Exponent's sales growth this year is expected to be 6.8% and 3.9% for next year.
Year-on-year quarterly revenue growth grew by 7.2%, now sitting on 434.85M for the twelve trailing months.
Volume
Today's last reported volume for Exponent is 157736 which is 47.07% below its average volume of 298021.
Exponent's sales growth for the next quarter is 13.4%. The company's growth estimates for the present quarter and the next is a negative 12.1% and negative -10.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 26%.
Volatility
Exponent's last day, last week, and last month's current intraday variation average was 1.05%, 1.15%, and 1.02%, respectively.
Exponent's highest amplitude of average volatility was 3.51% (day), 2.32% (last week), and 2.06% (last month), respectively.
Exponent's Stock Yearly Top and Bottom Value
Exponent's stock is valued at $106.74 at 11:22 EST, way under its 52-week high of $127.61 and way higher than its 52-week low of $83.49.
Exponent's Moving Average
Exponent's value is above its 50-day moving average of $97.48 and below its 200-day moving average of $107.46.4. W.W. Grainger (GWW)
9.3% sales growth and 52.39% return on equity
W.W. Grainger, Inc. provides MRO (maintenance, repair, operating) products and services throughout the United States, Canada, as well as internationally.
W.W. Grainger's sales growth this year is anticipated to be 9.5% and 7.6% for next year.
Year-on-year quarterly revenue growth grew by 14.2%, now sitting on 13.02B for the twelve trailing months.
Volume
Today's last reported volume for W.W. Grainger is 96549 which is 68.71% below its average volume of 308588.
W.W. Grainger's sales growth for the next quarter is 9.3%. The company's growth estimates for the present quarter and the next is 42.6% and 24.8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 52.39%.
Volatility
W.W. Grainger's last day, last week, and last month's current intraday variation average was 2.64%, 0.91%, and 1.19%, respectively.
W.W. Grainger's highest amplitude of average volatility was 3.72% (day), 3.31% (last week), and 2.66% (last month), respectively.
W.W. Grainger's Stock Yearly Top and Bottom Value
W.W. Grainger's stock is valued at $489.29 at 11:22 EST, under its 52-week high of $529.91 and way higher than its 52-week low of $391.16.
W.W. Grainger's Moving Average
W.W. Grainger's worth is under its 50-day moving average of $498.05 and above its 200-day moving average of $470.60.5. Integra LifeSciences Holdings Corporation (IART)
9.1% sales growth and 14.29% return on equity
Integra LifeSciences Holdings Corporation designs, produces, and markets surgical instruments and implants for neurosurgery and other general surgeries.
Integra LifeSciences Holdings Corporation's sales growth this year is expected to be 12.3% and 5.8% for next year.
Year-on-year quarterly revenue growth grew by 4.5%, now sitting on 1.53B for the twelve trailing months.
Volume
Today's last reported volume for Integra LifeSciences Holdings Corporation is 355624 which is 25.91% below its average volume of 480029.
Integra LifeSciences Holdings Corporation's sales growth for the next quarter is 9.1%. The company's growth estimates for the present quarter and the next is a negative 1.2% and 10.1%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.29%.
Volatility
Integra LifeSciences Holdings Corporation's last day, last week, and last month's current intraday variation average was 4.93%, 1.85%, and 1.52%, respectively.
Integra LifeSciences Holdings Corporation's highest amplitude of average volatility was 5.48% (day), 2.75% (last week), and 2.73% (last month), respectively.
Integra LifeSciences Holdings Corporation's Stock Yearly Top and Bottom Value
Integra LifeSciences Holdings Corporation's stock is valued at $64.47 at 11:22 EST, way below its 52-week high of $77.40 and above its 52-week low of $61.27.
Integra LifeSciences Holdings Corporation's Moving Average
Integra LifeSciences Holdings Corporation's worth is below its 50-day moving average of $65.17 and under its 200-day moving average of $67.80.6. First Eagle Alternative Capital BDC (FCRD)
6.5% sales growth and 9.42% return on equity
THL Credit Inc., a business development firm specializing on direct and fund-of-fund investments is known as THL Credit.
First Eagle Alternative Capital BDC's sales growth this year is anticipated to be 6.4% and 5.5% for next year.
Year-on-year quarterly revenue growth grew by 7.5%, now sitting on 31.4M for the twelve trailing months.
Volume
Today's last reported volume for First Eagle Alternative Capital BDC is 24582 which is 28.38% below its average volume of 34327.
First Eagle Alternative Capital BDC's sales growth for the next quarter is 6.5%. The company's growth estimates for the present quarter and the next is a negative 9.1% and 11.1%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.42%.
Volatility
First Eagle Alternative Capital BDC's last day, last week, and last month's current intraday variation average was 0.98%, 0.93%, and 0.89%, respectively.
First Eagle Alternative Capital BDC's highest amplitude of average volatility was 1.47% (day), 2.70% (last week), and 2.78% (last month), respectively.
First Eagle Alternative Capital BDC's Stock Yearly Top and Bottom Value
First Eagle Alternative Capital BDC's stock is valued at $4.12 at 11:22 EST, way under its 52-week high of $4.89 and higher than its 52-week low of $4.01.